Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Psychiatry. Feb 19, 2022; 12(2): 264-285
Published online Feb 19, 2022. doi: 10.5498/wjp.v12.i2.264
Published online Feb 19, 2022. doi: 10.5498/wjp.v12.i2.264
Insights into myelin dysfunction in schizophrenia and bipolar disorder
Marcela Valdés-Tovar, Departamento de Farmacogenética, Subdirección de Investigaciones Clí
Alejandra Monserrat Rodríguez-Ramírez, Leslye Rodríguez-Cárdenas, Carlo E Sotelo-Ramírez, Beatriz Camarena, Marco Antonio Sanabrais-Jiménez, Departamento de Farmacogenética, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City 14370, Mexico
Carlo E Sotelo-Ramírez, Jesús Argueta, Doctorado en Biología Experimental, Universidad Autó
Héctor Solís-Chagoyán, Jesús Argueta, Laboratorio de Neurofarmacología, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City 14370, Mexico
Germán Octavio López-Riquelme, Laboratorio de Socioneurobiología, Centro de Investigación en Ciencias Cognitivas, Universidad del Estado de Morelos, Cuernavaca 62209, Morelos, Mexico
Author contributions: Valdés-Tovar M contributed to the overall conception and design of the study; all authors carried out comprehensive literature search and wrote the first draft; Rodríguez-Ramírez AM contributed to the clinical perspective and figure design; Sotelo-Ramírez CE contributed to figure creation; Solís-Chagoyán H critically revised the manuscript; Valdés-Tovar M and Camarena B obtained funding; all authors assisted in a thorough revision of the manuscript and approved its final version.
Supported by Fondo Sectorial de Investigación para la Educación (FSIE SEP/CONACyT) to MV-T , No. 287115 ; and Fondo Sectorial de Investigación en Salud y Seguridad Social (FOSISS SS/IMSS/ISSSTE-CONACyT) to BC , No. 261459 .
Conflict-of-interest statement: Dr. Valdés-Tovar has received research funding from Fondo Sectorial de Investigación para la Educación (FSIE), SEP-CONACyT and Dr. Camarena has received research funding from Fondo Sectorial de Investigación en Salud y Seguridad Social (FOSISS), SS/IMSS/ISSSTE-CONACyT, during the conduct of the study.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Marcela Valdés-Tovar, PhD, Research Scientist, Departamento de Farmacogenética, Subdirección de Investigaciones Clínicas, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Calzada México-Xochimilco No. 101, Col. San Lorenzo-Huipulco, Tlalpan, Mexico City 14370, Mexico. mvaldes@imp.edu.mx
Received: May 31, 2021
Peer-review started: May 31, 2021
First decision: July 14, 2021
Revised: August 10, 2021
Accepted: January 17, 2022
Article in press: January 17, 2022
Published online: February 19, 2022
Peer-review started: May 31, 2021
First decision: July 14, 2021
Revised: August 10, 2021
Accepted: January 17, 2022
Article in press: January 17, 2022
Published online: February 19, 2022
Core Tip
Core Tip: Schizophrenia and bipolar disorder are multifactorial neuropsychiatric entities that share clinical manifestations as well as alterations to brain structure and function, genetic characteristics, and neurobiological pathways. Among the main pathophysiological mechanisms shared by these conditions is oligodendroglial dysfunction. Scientific evidence that ranges from the microscale cellular and subcellular levels to the macroscale connectomic level strongly supports overall myelin dysfunction and brain disconnection as hallmarks of schizophrenia and bipolar disorder.